Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Multimodal approaches combining various numbers of behavioral, neuroimaging and electrophysiological markers improves neuroprognosis performance in clinically unresponsive critical-care patients.
Analyses from the US Department of Veterans Affairs databases reported residual elevated risk and health burden of long COVID at 3 years in hospitalized individuals after SARS-CoV-2 infection.
AI-based three-dimensional genomic mapping reveals a large abundance of cancer precursors in normal pancreatic tissue — prompting new insights and research directions.
A whole-body scanner developed using a permanent 0.05-tesla magnet and deep learning has demonstrated its versatility in imaging various anatomical structures, showcasing its potential to address unmet clinical needs.
T1 mapping noninvasively assesses fibrosis in multiple organs and enables risk stratification of mortality and provides insights into shared and organ-specific pathways underlying fibrosis.
Accumulating data support the systemic benefits of semaglutide (and potentially other GLP-1RA-based therapies) in people with obesity, meaning that cardiologists and other clinicians must become familiar with prescribing them — particularly once market competition makes these drugs more accessible.
In a randomized clinical trial, treatment using a monoclonal antibody targeting interleukin-6 (IL-6) in patients with cardiovascular disease and/or diabetes who were receiving maintenance kidney dialysis reduced levels of inflammatory biomarkers at 12 weeks, including C-reactive protein, paving the way for a phase 3 trial.
In a pre-specified secondary analysis of the SELECT trial, once-weekly subcutaneous semaglutide 2.4 mg in patients with obesity was associated with a 22% reduction in the main 5-component kidney composite endpoint compared to patients on placebo.
A longitudinal multiomic dataset was assembled to characterize the immune landscape in myocardial infarction and chronic coronary syndromes. Multiomics factor analysis (MOFA) revealed immune signatures that associate with disease stage or treatment outcomes. This work opens new directions for future mechanistic and clinical studies on coronary artery disease and myocardial infarction.
A modeling study marking 50 years of vaccination through the Expanded Programme on Immunization of the World Health Organization highlights its lifesaving impact on infant and child health.
A multimodal deep learning prognostic model based on histopathology outperforms current gold standards for identifying patients with endometrial cancer with different outcomes, in multiple external validation cohorts.
A framework is presented for equitable and effective microbiome research partnerships between African researchers, international partners, healthcare professionals, policymakers and stakeholders.
The National Cancer Institute’s Office of Data Sharing is implementing a framework for data sharing and public access policies, which will empower innovation and maximize therapeutic benefits for the cancer community.
By leveraging paired microbiome and human gene expression data from pediatric patients who underwent hematopoietic cell transplantation, distinct lung–immune system–microorganism interactions were identified as important drivers of fatal lung injury.
Sustained safety outcomes were seen at 2-year follow-up after induced pluripotent stem cell-derived mesenchymal stromal cell infusion in 15 individuals with steroid-resistant acute graft-versus-host disease.